Form D · Pharmaceuticals

Cyclerion Therapeutics, Inc.

Cambridge, MA · CIK 0001755237

Offering snapshot reported May 25, 2023 · SEC filing

Reported sold
$5M
Offering amount: $5M
Investors reported
1
Form D · investor count
Minimum accepted
$0
Reported outside-investor minimum
First sale
May 19, 2023
As reported in this filing

What changed?

Latest filing versus its linked predecessor, where available.

No comparable changes in the displayed metrics.

Filing history

Scroll to see all columns →

FiledFiling typeReported soldChange vs linked filingInvestorsSource
May 25, 2023Initial$5,000,000No comparison1SEC filing
Jun 17, 2021Initial$18,028,000No comparisonNot reportedSEC filing
Aug 11, 2020Initial$24,250,000No comparison2SEC filing
Apr 17, 2019Initial$175,000,000No comparison49SEC filing

Offering details

Securities
Equity
Exemptions
06b
Duration over one year
No
Business combination
No
Sales commissions
$0
Finders' fees
$0
Form D file number
021-482661

Source: Form D, filed May 25, 2023. Minimum accepted may differ from a standard advertised minimum.

Fund connections

No confirmed ADV fund connection is available for this issuer.

People & organizations

Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.

People and organizations reported in Form D filings
NameReported role
Andreas Busch Executive
Kevin Churchwell Director
George Conrades Director
Mark G. Currie Executive
Errol De Souza Director
Marsha Fanucci Director
Cheryl Gault Executive
Anjeza Gjino Executive
Peter M. Hecht Director, Executive
William Huyett Executive
Steven Hyman Director
Ole Isacson Director
Stephanie Lovell Director
Terrance Mc Guire Director
Michael Mendelsohn Director
Amy Schulman Director

Issuer details

Industry: Pharmaceuticals (See others in industry)

Address:
245 First Street, 18th Floor
Cambridge, MA, 02142